药物开发 药物开发
Norhakim Yahya1, Scott J Pollack1, Richard Margolin1
1TauC3 Biologics Limited, Stevenage, Hertfordshire, United Kingdom.
新型抗体TBL-100专门针对有毒的tauC3片段,对单体和小分子形式都有很高的亲和力. 这种特异性提供了通过中断病理性陶传播来治疗陶病的潜力.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 陶蛋白异常是阿尔茨海默病 (AD) 和其他陶病的核心原因.
- 以前的tau抗体由于对致病性tau物种的亲和力或特异性不足而失败.
- 人性化的单克隆抗体TBL-100针对tauC3,一种具有高亲和度和特异性的有毒C末端片段.
研究的目的:
- 研究TBL-100与tauC3.3的结合特性.
- 为了确定TBL-100是否结合了难以接近的表皮质或裂形成的新表皮质.
- 评估TBL-100针对有毒的tau物种和寡合物的潜力.
主要方法:
- 与酶相关的免疫吸收试验 (ELISA) 用于确定TBL-100对单体和小体tauC3.3的亲和力.
- 表面等离子体共振 (SPR) 来评估TBL-100与合成酸的结合.
- 结合tauC3的TBL-100与全长tau (FLT) 的比较.
主要成果:
- TBL-100对tauC3表现出极好的末端特异性,优先结合到以Asp421结束的序列.
- 对于具有额外C端氨基酸的,结合亲和力显著降低.
- TBL-100结合了单和寡的tauC3与皮科莫尔亲缘关系,但不是FLT.
结论:
- TBL-100对致病性tauC3片段具有很高的亲和力和特异性.
- 它结合寡合体tauC3的能力表明,它有可能抑制病理的传播.
- TBL-100代表了对病的有希望的治疗候选者.
更多相关视频
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
相关概念视频
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation
